-+ 0.00%
-+ 0.00%
-+ 0.00%

JOHNSON & JOHNSON ANNOUNCES NEW PHASE 2 NIPOCALIMAB STUDY DATA IN SJÖGREN'S DISEASE THAT REVEAL INSIGHTS ON IMPORTANCE OF SYMPTOM IMPROVEMENTS MOST VALUED BY PATIENTS

Reuters·11/07/2026 15:03:00

Please log in to view news